Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DARE Dare Bioscience	$2.11 -4.1%	$2.55	$1.83 ▼ $9.19	$19.05M	1.11	629,676 shs	147,571 shs
EQ Equillium	$1.34 +17.5%	$0.45	$0.27 ▼ $1.50	$47.87M	1.15	3.46 million shs	5.26 million shs
GLTO Galecto	$3.37 -0.3%	$3.44	$2.01 ▼ $15.13	$4.45M	1.35	120,964 shs	2,472 shs
IMNN Imunon	$6.48 +1.3%	$11.24	$4.83 ▼ $41.22	$15.81M	2.16	420,263 shs	70,766 shs

Analysts Agree—These Gold Picks Outshine the Rest

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DARE Dare Bioscience	0.00%	+14.58%	-12.70%	-24.66%	-38.38%
EQ Equillium	0.00%	+130.21%	+174.63%	+196.88%	+45.20%
GLTO Galecto	0.00%	+0.74%	-5.15%	+10.91%	-76.53%
IMNN Imunon	0.00%	-10.86%	-22.71%	-9.24%	-62.57%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
DARE Dare Bioscience	2.3549 of 5 stars	3.5	5.0	2.0	0.0	0.0
EQ Equillium	2.8048 of 5 stars	3.2	5.0	2.9	1.7	0.0
GLTO Galecto	3.7976 of 5 stars	3.5	5.0	3.6	1.7	1.3
IMNN Imunon	1.5234 of 5 stars	3.4	2.0	1.1	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DARE Dare Bioscience	3.00	Buy	$12.00	468.72% Upside
EQ Equillium	2.33	Hold	$3.00	123.88% Upside
GLTO Galecto	3.00	Buy	$10.00	196.74% Upside
IMNN Imunon	2.75	Moderate Buy	$232.50	3,487.96% Upside

Current Analyst Ratings Breakdown

Latest GLTO, EQ, IMNN, and DARE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
5/19/2025	IMNN Imunon	D Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/19/2025	IMNN Imunon	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold

(Data available from 8/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DARE Dare Bioscience	$10K	1,905.33	N/A	N/A	($0.69) per share	-3.06
EQ Equillium	$41.10M	1.16	N/A	N/A	$0.54 per share	2.48
GLTO Galecto	N/A	N/A	N/A	N/A	$10.99 per share	N/A
IMNN Imunon	$500K	31.62	N/A	N/A	$3.82 per share	1.70

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DARE Dare Bioscience	-$4.05M	-$2.14	N/A	N/A	N/A	N/A	N/A	-94.95%	N/A
EQ Equillium	-$8.07M	-$0.56	N/A	N/A	N/A	-19.62%	-114.69%	-78.89%	N/A
GLTO Galecto	-$21.44M	-$13.13	N/A	N/A	N/A	N/A	-115.70%	-95.42%	N/A
IMNN Imunon	-$18.62M	-$12.95	N/A	N/A	N/A	N/A	-405.07%	-158.41%	11/6/2025 (Estimated)

Latest GLTO, EQ, IMNN, and DARE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	DARE Dare Bioscience	-$0.55	-$0.45	+$0.10	-$0.45	$0.14 million	($0.02) million
8/14/2025	Q2 2025	EQ Equillium	-$0.14	-$0.16	-$0.02	-$0.16	N/A	N/A
8/5/2025	Q2 2025	GLTO Galecto	N/A	-$2.60	N/A	-$2.60	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
DARE Dare Bioscience	N/A	N/A	N/A	N/A	N/A
EQ Equillium	N/A	N/A	N/A	N/A	N/A
GLTO Galecto	N/A	N/A	N/A	N/A	N/A
IMNN Imunon	N/A	N/A	N/A	N/A	N/A

Latest GLTO, EQ, IMNN, and DARE Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/28/2025	IMNN Imunon	quarterly	$0.15	8.57%	8/7/2025	8/7/2025	8/21/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DARE Dare Bioscience	N/A	0.56	0.56
EQ Equillium	N/A	2.70	2.70
GLTO Galecto	N/A	4.96	4.96
IMNN Imunon	N/A	1.30	1.30

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DARE Dare Bioscience	6.70%
EQ Equillium	27.05%
GLTO Galecto	14.20%
IMNN Imunon	4.47%

Insider Ownership

Company	Insider Ownership
DARE Dare Bioscience	4.80%
EQ Equillium	30.30%
GLTO Galecto	10.80%
IMNN Imunon	5.96%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DARE Dare Bioscience	30	9.03 million	8.60 million	Not Optionable
EQ Equillium	40	35.72 million	24.90 million	Not Optionable
GLTO Galecto	40	1.32 million	1.18 million	Optionable
IMNN Imunon	30	2.44 million	2.30 million	Not Optionable

GLTO, EQ, IMNN, and DARE Headlines

Recent News About These Companies

Imunon, Inc. Advances Phase 3 Trial for Innovative Cancer Treatment

August 14, 2025 | msn.com

Imunon, Inc.’s Ongoing Clinical Trial: Potential Game-Changer for Ovarian Cancer Treatment?

August 14, 2025 | tipranks.com

Imunon (NASDAQ:IMNN) Stock Rating Upgraded by Wall Street Zen

August 11, 2025 | americanbankingnews.com

Analysts Set Expectations for Imunon Q3 Earnings

August 9, 2025 | americanbankingnews.com

IMNN: First Patient Dosed in Phase 3 OVATION 3 Trial…

August 8, 2025 | finance.yahoo.com

Imunon, Inc. Earnings Call Highlights Progress and Challenges

August 5, 2025 | tipranks.com

Imunon Q2 2025 Earnings Preview

August 5, 2025 | msn.com

6IMNN : Insights into Imunon's Upcoming Earnings

August 5, 2025 | benzinga.com

Imunon puts COVID-19 vaccine on ice and seeks partner amid cash crunch

August 5, 2025 | fiercebiotech.comF

Imunon outlines rapid OVATION 3 Phase III trial launch and initiates 15% stock dividend to support shareholder value

August 5, 2025 | msn.com

IMUNON Recaps Highlights from 2025 Second Quarter Financial Results Conference Call

August 5, 2025 | globenewswire.com

Imunon, Inc. (IMNN) Q2 2025 Earnings Call Transcript

August 5, 2025 | seekingalpha.com

IMUNON Reports Second Quarter 2025 Financial Results and Provides Business Update

August 5, 2025 | globenewswire.com

Imunon Doses First Patient With Experimental Cancer Drug In Late-Stage Trial: Retail Thinks Company Is Undervalued

July 30, 2025 | msn.com

IMUNON (IMNN) Stock Is Trending Wednesday: What's Going On?

July 30, 2025 | benzinga.com

IMUNON Announces First Patient Dosed in Phase 3 OVATION 3 Study of IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer

July 30, 2025 | globenewswire.com

IMUNON to Hold Second Quarter 2025 Financial Results and Business Update Conference Call on Tuesday, August 5, 2025

July 29, 2025 | globenewswire.com

IMUNON Announces Stock Dividend Boosting Shareholder Value

July 28, 2025 | globenewswire.com

Imunon, Inc. Advances DNA Vaccine Study for COVID-19 Variants

July 25, 2025 | tipranks.com

IMUNON Announces Reverse Stock Split

July 23, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

GLTO, EQ, IMNN, and DARE Company Descriptions

Dare Bioscience NASDAQ:DARE

$2.11 -0.09 (-4.09%)

Closing price 04:00 PM Eastern

Extended Trading

$2.11 0.00 (-0.19%)

As of 05:08 PM Eastern

Daré Bioscience, Inc., a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older. It is developing Ovaprene, a hormone-free, monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia on demand for the treatment of female sexual arousal disorder; DARE-HRT1 to treat moderate to-severe vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of moderate-to-severe dyspareunia or pain during sexual intercourse; and DARE-CIN to treat cervical intraepithelial neoplasia and other human papillomavirus related pathologies. The company is also developing DARE-PDM1 for the treatment of primary dysmenorrhea; DARE-204 and DARE-214, an injectable formulations contraception of etonogestrel designed to provide contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. In addition, it is developing DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design that controlled contraceptive option; DARE-LBT, a novel hydrogel formulation for vaginal delivery of live biotherapeutics to support vaginal health; DARE-GML, a multi-target antimicrobial agent; DARE-RH1, a novel approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; and DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein. Daré Bioscience, Inc. is headquartered in San Diego, California.

Equillium NASDAQ:EQ

$1.34 +0.20 (+17.54%)

Closing price 04:00 PM Eastern

Extended Trading

$1.34 0.00 (0.00%)

As of 05:05 PM Eastern

Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications. In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.

Galecto NASDAQ:GLTO

$3.37 -0.01 (-0.30%)

Closing price 03:57 PM Eastern

Extended Trading

$3.38 +0.01 (+0.18%)

As of 04:01 PM Eastern

Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.

Imunon NASDAQ:IMNN

$6.48 +0.08 (+1.25%)

Closing price 04:00 PM Eastern

Extended Trading

$6.48 0.00 (0.00%)

As of 05:05 PM Eastern

Imunon, Inc., a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company's lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma. In addition, the company develops non-viral DNA technology across four modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; PlaCCine for the coding of viral antigens that can elicit a strong immunological response; FixPlas for the application of Imunon's DNA technology to produce universal cancer vaccines; and IndiPlas, which is in the discovery phase for the development of personalized cancer vaccines or neoepitope cancer vaccines. Imunon, Inc. was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. The company was founded in 1982 and is headquartered in Lawrenceville, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time